Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Opinion & Analysis Kintara Therapeutics Inc KTRA

Kintara Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development and commercialization of new cancer therapies. It is focused on the development of novel cancer therapies for patients with unmet medical needs. Its two candidates include VAL-083 and REM-001. VAL-083 is a novel, validated, deoxyribonucleic acid (DNA)-targeting agent, for the treatment of... see more

Opinion & Analysis (NDAQ:KTRA)

    Analyst Sees Tenbagger in Biotech Firm with 'Favorable Updates'

    Streetwise Reports April 25, 2018

    VIDEO: DelMar Pharmaceuticals With Plans To Develop And Commercialize Proven Cancer Therapies

    BTV-Business Television June 24, 2014